Document is current
Any future updates will be listed below
-
Authors
Ott, Christian
Jung, Susanne
Korn, Manuel
Kannenkeril, Dennis
Bosch, Agnes
Kolwelter, Julie
Striepe, Kristina
Bramlage, Peter
Schiffer, Mario
Schmieder, Roland E. https://orcid.org/0000-0003-2356-5883
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02752113 at ClinicalTrials.govDocuments that mention this clinical trial
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
https://doi.org/10.1186/s12933-021-01358-8
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 4 June 2021
Accepted: 31 July 2021
First Online: 4 September 2021
Change Date: 26 February 2022
Change Type: Update
Change Details: Open access funding note missed in the original publication. Now, it has been added in the Funding section.
Declarations
:
: The study protocol was approved by the Local Ethics Committee (University of Erlangen-Nürnberg, Germany). Written informed consent was obtained prior to study inclusion.
: Not applicable.
: PB received research funding from Boehringer for this and other studies; RES has received speaker fees and advisory board fees from Boehringer Ingelheim Pharma GmbH & Co KG.
